NELLY ZUNIGA: Open Payments
NPI 1194405803 · LONGVIEW, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,215 in 40 payments from 9 companies in 2025. Trend: 2023 $423 · 2024 $1,196 · 2025 $1,215
Food & beverage: $1,215
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $318 |
| Teva Pharmaceuticals USA, Inc. | 6 | $302 |
| ABBVIE INC. | 11 | $222 |
| Vanda Pharmaceuticals Inc. | 1 | $125 |
| Otsuka America Pharmaceutical, Inc. | 4 | $98 |
| Lundbeck LLC | 4 | $71 |
| Alkermes, Inc. | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Indivior Inc. | 1 | $15 |
Products named: CAPLYTA, UZEDY, VRAYLAR, REXULTI, FANAPT, AUSTEDO XR, LYBALVI, TRINTELLIX.
Industry payments across TX — which companies pay providers there.
